Published in Prostate Cancer Prostatic Dis on June 12, 2012
The relationship between nutrition and prostate cancer: is more always better? Eur Urol (2012) 1.66
Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol (2013) 1.22
A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality. Cancer Causes Control (2015) 1.11
Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med (2015) 0.98
A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer--the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis (2014) 0.93
Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am (2013) 0.92
Dietary polyphenols in prevention and treatment of prostate cancer. Int J Mol Sci (2015) 0.89
Pomegranate Bioactive Constituents Suppress Cell Proliferation and Induce Apoptosis in an Experimental Model of Hepatocellular Carcinoma: Role of Wnt/ β -Catenin Signaling Pathway. Evid Based Complement Alternat Med (2013) 0.87
A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy. Cancer Prev Res (Phila) (2013) 0.86
Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy. Oxid Med Cell Longev (2015) 0.83
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. Am J Cancer Ther Pharmacol (2014) 0.82
Efficacy and safety of pomegranate medicinal products for cancer. Evid Based Complement Alternat Med (2015) 0.81
Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial. J Cancer (2013) 0.81
Pomegranate and its components as alternative treatment for prostate cancer. Int J Mol Sci (2014) 0.81
Pomegranate polyphenols lower lipid peroxidation in adults with type 2 diabetes but have no effects in healthy volunteers: a pilot study. J Nutr Metab (2013) 0.80
Pomegranate extracts and cancer prevention: molecular and cellular activities. Anticancer Agents Med Chem (2013) 0.79
Polyphenols are responsible for the proapoptotic properties of pomegranate juice on leukemia cell lines. Food Sci Nutr (2013) 0.79
A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis (2014) 0.79
Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. Evid Based Complement Alternat Med (2013) 0.78
Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention. Int J Nanomedicine (2015) 0.78
A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis (2015) 0.78
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. Prostate (2015) 0.77
Future prospects in the diagnosis and management of localized prostate cancer. ScientificWorldJournal (2013) 0.77
A pilot study to investigate if New Zealand men with prostate cancer benefit from a Mediterranean-style diet. PeerJ (2015) 0.77
Pomegranate Supplementation Protects against Memory Dysfunction after Heart Surgery: A Pilot Study. Evid Based Complement Alternat Med (2013) 0.76
A Perspective on Prostate Carcinogenesis and Chemoprevention. Curr Pharmacol Rep (2015) 0.76
Celastrol, an active constituent of the TCM plant Tripterygium wilfordii Hook.f., inhibits prostate cancer bone metastasis. Prostate Cancer Prostatic Dis (2017) 0.75
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM). Nutrients (2016) 0.75
Food-based natural products for cancer management: Is the whole greater than the sum of the parts? Semin Cancer Biol (2016) 0.75
Pomegranate for Prevention and Treatment of Cancer: An Update. Molecules (2017) 0.75
Could Pomegranate Juice Help in the Control of Inflammatory Diseases? Nutrients (2017) 0.75
A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer. Prostate (2017) 0.75
A review of pomegranate in prostate cancer. Prostate Cancer Prostatic Dis (2017) 0.75
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol (2006) 4.69
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol (2006) 2.29
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res (2006) 1.86
Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A (2005) 1.78
Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr (2006) 1.51
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer (2004) 1.31
Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med (2010) 1.26
Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food (2004) 1.26
Prostate cancer prevention through pomegranate fruit. Cell Cycle (2006) 1.17
Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist (2003) 1.07
Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol (2008) 1.06
Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol (2004) 1.06
Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis. Dose Response (2009) 1.02
Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol (1999) 1.01
Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res (2009) 1.00
The bioactivity of pomegranate: impact on health and disease. Crit Rev Food Sci Nutr (2011) 0.99
The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat (1998) 0.97
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (2001) 6.29
Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A (1994) 3.38
Temporal variability in urinary concentrations of phthalate metabolites, phytoestrogens and phenols among minority children in the United States. Environ Res (2007) 3.31
A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med (2000) 3.24
Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A (2001) 3.02
A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry (2000) 2.88
Ischemic mitral valve reconstruction and replacement: comparison of long-term survival and complications. J Thorac Cardiovasc Surg (2001) 2.44
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry (1997) 2.29
Social support and depressed mood: a structural analysis. J Health Soc Behav (1999) 2.23
Evaluation of a school-based HIV/AIDS peer-led prevention programme: the first intervention trial for children of migrant workers in China. Int J STD AIDS (2010) 2.13
A comparison of family medicine research in research intense and less intense institutions. Arch Fam Med (2001) 2.10
Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther (2000) 2.04
Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene (2009) 2.01
Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation (1999) 1.98
Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J Biol Chem (2001) 1.94
The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc Natl Acad Sci U S A (2001) 1.92
Urinary bisphenol A concentrations and ovarian response among women undergoing IVF. Int J Androl (2009) 1.75
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res (2001) 1.68
Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics (1997) 1.68
Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology (1995) 1.62
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia (2010) 1.61
Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. Mol Cell Biol (2000) 1.58
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
HIV and syphilis in migrant workers in eastern China. Sex Transm Infect (2006) 1.54
HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression. Mol Cell Biol (2001) 1.49
In vivo inhibition of nuclear factor-kappa B activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol (1997) 1.47
Solution structure of P22 transcriptional antitermination N peptide-boxB RNA complex. Nat Struct Biol (1998) 1.45
Segmentation of pulmonary nodules in thoracic CT scans: a region growing approach. IEEE Trans Med Imaging (2008) 1.44
Identification and characterization of circulating prostate carcinoma cells. Cancer (2000) 1.41
Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology (2011) 1.41
p75NTR and the concept of cellular dependence: seeing how the other half die. Cell Death Differ (1998) 1.40
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res (2001) 1.34
Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci U S A (1999) 1.27
The association of body weight, dietary intake, and energy expenditure with dietary restraint and disinhibition. Obes Res (1995) 1.24
Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract (2007) 1.24
Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther (2001) 1.23
Association of body mass with dietary restraint and disinhibition. Appetite (1995) 1.22
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene (2010) 1.16
Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb Haemost (2001) 1.16
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther (2008) 1.16
Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy. Eur J Cancer (2012) 1.16
Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high-level resistance to aminoglycosides. Eur J Clin Microbiol Infect Dis (2010) 1.14
Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med (1998) 1.13
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res (2001) 1.13
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer (2011) 1.12
Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int (2009) 1.12
Pyrrolidine dithiocarbamate prevents I-kappaB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol (1999) 1.10
Complete androgen blockade for prostate cancer: what went wrong? J Urol (2000) 1.06
Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle. J Pediatr Endocrinol Metab (2003) 1.06
Long-term follow-up study on peer-led school-based HIV/AIDS prevention among youths in Shanghai. Int J STD AIDS (2008) 1.05
Retinal capillary pericyte apoptosis in early human diabetic retinopathy. Chin Med J (Engl) (1997) 1.02
Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Ther (2000) 1.02
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol (2011) 1.01
Dynamics of placodal lineage development revealed by targeted transgene expression. Dev Dyn (1999) 1.00
Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis (2009) 1.00
Efficacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction: a randomized, placebo-controlled, double-blind, crossover study. Int J Impot Res (2007) 0.99
Cumulus cell function during bovine oocyte maturation, fertilization, and embryo development in vitro. Mol Reprod Dev (1995) 0.97
HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. Curr Cancer Drug Targets (2009) 0.94
The incidence and management of rectal injury associated with radical prostatectomy in a community based urology practice. J Urol (1995) 0.94
Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia (2012) 0.94
Recent progress in research on Tripterygium: a male antifertility plant. Contraception (1995) 0.94
Ecology-based screen identifies new metabolites from a Cordyceps-colonizing fungus as cancer cell proliferation inhibitors and apoptosis inducers. Cell Prolif (2009) 0.93
Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol (2000) 0.93
Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. J Inherit Metab Dis (1998) 0.93
Naphthalene-induced oxidative stress and DNA damage in cultured macrophage J774A.1 cells. Free Radic Biol Med (1998) 0.92
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Ann Oncol (2012) 0.92
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene (2008) 0.92
Association of a single nucleotide polymorphism in the calpastatin gene with carcass and meat quality traits of beef cattle. J Anim Sci (2006) 0.92
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 0.92
Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res (2006) 0.91
High-resolution YAC-cosmid-STS map of human chromosome 13. Genomics (1998) 0.91
Dimerization-dependent block of the proapoptotic effect of p75(NTR). J Neurosci Res (2000) 0.91
Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab (2009) 0.91
Down-regulation of angiotensin II receptor subtypes and desensitization of cyclic GMP production in neuroblastoma N1E-115 cells. J Neurochem (1993) 0.91
Analysis of candidate genes on chromosome 2 in oral cleft case-parent trios from three populations. Hum Genet (2006) 0.91
Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia (1996) 0.90
Neurotrophin dependence domain: a domain required for the mediation of apoptosis by the p75 neurotrophin receptor. J Mol Neurosci (2000) 0.90
Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry (1998) 0.90
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs (2000) 0.90
Computer-assisted detection for CT colonography: external validation. Clin Radiol (2006) 0.90
3D HCCH-COSY-TOCSY experiment for the assignment of ribose and amino acid side chains in 13C labeled RNA and protein. J Biomol NMR (1998) 0.88
Healthcare resource utilization among haemophilia A patients in the United States. Haemophilia (2011) 0.88
Angiotensin-induced cyclic GMP production is mediated by multiple receptor subtypes and nitric oxide in N1E-115 neuroblastoma cells. J Neurochem (1992) 0.88
Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology (2000) 0.88
Extracellular matrix of retinal pigment epithelium regulates choriocapillaris endothelial survival in vitro. Exp Eye Res (1997) 0.88
In vivo measurement of ureagenesis with stable isotopes. J Inherit Metab Dis (1998) 0.87
The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int (2000) 0.87
Association of single nucleotide polymorphisms in the leptin gene with carcass and meat quality traits of beef cattle. J Anim Sci (2005) 0.87
Evaluation of cardiovascular risk factors, events, and costs across four BMI categories. Obesity (Silver Spring) (2013) 0.86
Sequence-dependent interactions of two forms of UvrC with DNA helix-stabilizing CC-1065-N3-adenine adducts. Biochemistry (2001) 0.86
Cystic hygroma of the breast. Arch Pathol Lab Med (1986) 0.86
NCCN: Palliative care. Cancer Control (2001) 0.85
TP63 gene mutations in Chinese P63 syndrome patients. J Dent Res (2010) 0.85
Characterization of differentially expressed genes in ovarian cancer by cDNA microarrays. Int J Gynecol Cancer (2005) 0.84
Expression of apoptosis regulatory genes by retinal pericytes after rapid glucose reduction. Invest Ophthalmol Vis Sci (1998) 0.84
MX1 exon 13 polymorphisms in broiler breeder chickens and associations with commercial traits. Anim Genet (2007) 0.84
Associations of BF2 alleles with antibody titres and production traits in commercial pure line broiler chickens. Anim Genet (2007) 0.84
Increased Rate of Sporadic and Recurrent Rare Genic Copy Number Variants in Parkinson's Disease Among Ashkenazi Jews. Mol Genet Genomic Med (2013) 0.84